Deeter Investments
CNTX icon

Deeter Investments’s Context Therapeutics CNTX Stock Holding History

Deeter Investments’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$262K – 110
2026
Q1 		$262K Hold
100,000
– – 0.03% 97
2025
Q4 		$147K Buy
+100,000
New +$117K 0.03% 99

Other funds holding CNTX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Nextech Invest
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avidity Partners Management
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Deeter Investments's CNTX Position: Q2 2026 in Review

Deeter Investments sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 100,000 shares — an estimated $262K sold.

Deeter Investments first reported a position in CNTX in Q4 2025 and held it in 2 quarters. The position peaked at $262K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Deeter Investments reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Deeter Investments sold 100,000 Context Therapeutics shares in Q2 2026, an estimated $262K.
  • Deeter Investments first reported a position in Context Therapeutics in Q4 2025 and held it in 2 quarters.
  • Deeter Investments's Context Therapeutics position peaked at $262K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.